Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

LAmbre™ II Occlusore dell'Auricola Atriale Sinistra e Sistema di Consegna dell'Occlusore per Pazienti con Fibrillazione Atriale Non Valvolare (LAmbre2)

15 settembre 2026 aggiornato da: Dr So Chak Yu kent, Prince of Wales Hospital, Shatin, Hong Kong

Uno Studio di Primo Uomo (FIM) dell'Occlusore dell'Auricolo Sinistro LAmbre™ II e del Sistema di Erogazione dell'Occlusore per Pazienti con Fibrillazione Atriale Non Valvolare

Worldwide, atrial fibrillation (AF) is the most common cardiac arrhythmia in adults. The prevalence of AF gradually increases with age; its prevalence is 0.5% ~ 0.8% among 45 ~ 59 year-olds, 1.8% ~ 5.9% among 60 ~ 69 year-olds, and 6.7% ~17.9% among > 79 year-olds. Thromboembolic complications are the leading cause of death and disability in patients with AF, with ischemic stroke being the most common complication. AF significantly increases the risk of stroke by 3- to 5-fold due to thrombosis caused by abnormal atrial beat. The overall risk of ischemic stroke in patients with AF is 20% ~ 30%, and strokes due to atrial fibrillation account for 20% of all strokes.

In the current 2023 ACC/AHA/ACCP/HRS Guideline, percutaneous LAAC has been classified as a Class 2a indication for stroke prevention in patients with AF, a moderate to high risk of stroke, and a contraindication to long-term oral anticoagulation due to a nonreversible cause. However, the implantation procedure does have adverse effects which include serious pericardial effusion, procedure-related ischemic stroke, and device embolization. Due to the anatomical diversity of the LAA, certain patients are not candidates for this device.

The LAmbre™ Left Atrial Appendage Closure System, manufactured by Lifetech Scientific (Shenzhen) Co.Ltd., is the first generation of LAmbre LAAO device which is CE-marked and is current approved in Hong Kong Hospital Authority for regular clinical use. It consists of a LAA Occluder and a Delivery System and is a percutaneous transcatheter device intended to prevent thrombus embolization from the left atrial appendage in patients who have nonvalvular atrial fibrillation.

This self-expanding LAA Occluder consists of an umbrella and a cover connected by a central waist. Although the first generation of LAmbre LAAO device is associated with high implantation success rate of 99.7% and a relatively low major procedure-related complication rate of 2.9%, to better match the challenging anatomy of the LAA and to further improve procedural safety, the first generation of LAmbre LAAO device has been upgraded.

The LAmbre™ II Left Atrial Appendage Occluder, designed to prevent thrombus embolization and reduce the risk of bleeding events in patients with non-valvular atrial fibrillation, is being evaluated in a prospective, single-center, single-arm First In Man (FIM) study. The study, conducted at the Prince of Wales Hospital, Chinese University of Hong Kong, aims to assess the preliminary safety and feasibility of the device and its Occluder Delivery System in 10 subjects who are at increased risk for stroke and systemic embolism, either due to their anticoagulation therapy eligibility or contraindications.

The enrollment period is expected to take approximately 6 months and subjects will have follow-up before discharge and at 30 days, 3M, 6M, 12M months post-operation. The total study duration is expected to be approximately 19 months.

Panoramica dello studio

Stato

Attivo, non reclutante

Tipo di studio

Interventistico

Iscrizione (Stimato)

10

Fase

  • Non applicabile

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

      • Shatin, Hong Kong
        • The Chinese University of Hong Kong

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

18 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  • The patient age ≥18 years;
  • The patient has documented paroxysmal, persistent, or permanent non-valvular atrial fibrillation;
  • The patient has a CHA2DS2-VASc score of ≥ 2 in men and CHA2DS2-VASc score of ≥ 3 in women;
  • The patient is recommended for oral anticoagulation therapy, but there is an appropriate rationale for seeking a non-pharmacologic alternative to oral anticoagulation;
  • The patient is deemed suitable for LAA closure by the site investigator and a clinician not a part of the procedural team in the shared decision-making process, and this determination has been documented in the patient's medical record;
  • The patient is willing and able to comply with the required medication post-procedure and follow-up evaluations;
  • The patient (or his or her legally authorized representative) has been informed of the nature of the study, agrees to its provisions, and has been provided written informed consent approved by the appropriate Institutional Review Board (IRB) or Ethics Committee (EC).

Exclusion Criteria:

  • 1. Pregnant or nursing patients and those who plan pregnancy during the study period. Female patients of childbearing potential must have a negative pregnancy test (per site standard test) within 7 days prior to the index procedure;
  • Patients with atrial fibrillation that is defined by a single occurrence, or that is transient or reversible (e.g., secondary to CABG, an interventional procedure, pneumonia, or hyperthyroidism);
  • Patients who require long-term anticoagulation for a condition other than atrial fibrillation;
  • Bleeding diathesis or coagulopathy;
  • Patients with rheumatic mitral valve disease, known severe mitral stenosis requiring surgical or percutaneous valve replacement, or existing mechanical valve prosthesis;
  • Active infection with bacteremia;
  • Known hypersensitivity or contraindication to aspirin, clopidogrel, heparin, any device material or component (nickel titanium, PET, polypropylene), and/or contrast sensitivity;
  • Prior atrial septal defect (ASD) or patient foramen ovale (PFO) surgical repair or implantation of closure device;
  • Left atrial appendage is obliterated and surgical ligated;
  • Underwent any cardiac or non-cardiac interventional or surgical procedure within 30 days prior to the procedure or planned to have the interventional or surgical procedure within 60 days after implant procedure (e.g., cardioversion, ablation, percutaneous coronary intervention, cataract surgery, etc.);
  • Recent (within 90 days prior to procedure) stroke, transient ischemic attack, or myocardial infarction;
  • New York Heart Association Class IV;
  • Patients with severe renal failure (estimated glomerular filtration rate<30 ml/min/1.73m2);
  • Known asymptomatic carotid artery disease with>70% diameter stenosis OR symptomatic carotid disease (>50% diameter stenosis with ipsilateral stroke or TIA). Subjects with prior carotid endarterectomy or carotid stent placement may be enrolled, provided that known diameter stenosis is <50%;
  • Life expectancy is less than 1 year;
  • Current participation in another investigational drug or device study.

Echocardiographic Exclusion Criteria:

  • Left atrial appendage anatomy cannot accommodate the LAmbre II LAA Occluder per manufacturer IFU;
  • LVEF <30%;
  • Intracardiac thrombus or dense spontaneous echo contrast, as visualized by TEE prior to implant;
  • Presence of a high-risk patent foramen ovale (PFO), defined as an atrial septal aneurysm (excursion >15 mm or length >15 mm) or large shunt (early, within 3 beats and/or substantial passage of 20 bubbles);
  • Existing circumferential pericardial effusion >5 mm;
  • Moderate or severe mitral valve stenosis (mitral valve area <1.5 cm2);
  • Complex atheroma with mobile plaque of the descending aorta and/or aortic arch;
  • Presence of a cardiac tumor

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: N / A
  • Modello interventistico: Assegnazione di gruppo singolo
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Intervento

The LAmbre™ II Left Atrial Appendage Occluder, designed to prevent thrombus embolization and reduce the risk of bleeding events in patients with non-valvular atrial fibrillation

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
LAA closure success rate
Lasso di tempo: 3 months post-procedure

complete LAA closure or peri-device residual leak ≤3 mm measured by TEE at 3 months post-procedure

3 months post-procedure
Procedural complication rate
Lasso di tempo: peri-procedure

Rate of complication rate peri-procedure

peri-procedure

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Rate of death
Lasso di tempo: Perioperative

Rate of death at discharge

Perioperative
Rate of stroke
Lasso di tempo: Perioperative

Rate of stroke at discharge

Perioperative
Rate of stroke
Lasso di tempo: At 30 days post-OP

Rate of stroke at 30 days post-OP

At 30 days post-OP
Rate of stroke
Lasso di tempo: At 6 months post-OP

Rate of stroke at 6 months post-OP

At 6 months post-OP
Rate of stroke
Lasso di tempo: At 12 months post-OP

Rate of stroke at 12 months post-OP

At 12 months post-OP
Rate of systemic embolism
Lasso di tempo: Perioperative

Rate of systemic embolism at discharge

Perioperative
Rate of systemic embolism
Lasso di tempo: At 30 days post-OP

Rate of systemic embolism at 30 days post-OP

At 30 days post-OP
Rate of systemic embolism
Lasso di tempo: At 3 months post-OP

Rate of systemic embolism at 3 months post-OP

At 3 months post-OP
Rate of systemic embolism
Lasso di tempo: At 6 months post-OP

Rate of systemic embolism at 6 months post-OP

At 6 months post-OP
Rate of systemic embolism
Lasso di tempo: At 12 months post-OP

Rate of systemic embolism at 12 months post-OP

At 12 months post-OP
Rate of pericardial effusion with tamponade
Lasso di tempo: Perioperative

Rate of pericardial effusion with tamponade at discharge

Perioperative
Rate of pericardial effusion with tamponade
Lasso di tempo: At 30 days post-OP

Rate of pericardial effusion with tamponade at 30 days post-OP

At 30 days post-OP
Rate of pericardial effusion with tamponade
Lasso di tempo: At 3 months post-OP

Rate of pericardial effusion with tamponade at 3 months post-OP

At 3 months post-OP
Rate of pericardial effusion with tamponade
Lasso di tempo: At 6 months post-OP

Rate of pericardial effusion with tamponade at 6 months post-OP

At 6 months post-OP
Rate of pericardial effusion with tamponade
Lasso di tempo: At 12 months post-OP

Rate of pericardial effusion with tamponade at 12 months post-OP

At 12 months post-OP
Rate of pericardial effusion requiring drainage
Lasso di tempo: Perioperative

Rate of pericardial effusion requiring drainage at discharge

Perioperative
Rate of pericardial effusion requiring drainage
Lasso di tempo: At 30 days post-OP

Rate of pericardial effusion requiring drainage at 30 days post-OP

At 30 days post-OP
Rate of pericardial effusion requiring drainage
Lasso di tempo: At 3 months post-OP

Rate of pericardial effusion requiring drainage at 3 months post-OP

At 3 months post-OP
Rate of pericardial effusion requiring drainage
Lasso di tempo: At 6 months post-OP

Rate of pericardial effusion requiring drainage at 6 months post-OP

At 6 months post-OP
Rate of pericardial effusion requiring drainage
Lasso di tempo: At 12 months post-OP

Rate of pericardial effusion requiring drainage at 12 months post-OP

At 12 months post-OP
Rate of device embolization
Lasso di tempo: Perioperative

Rate of device embolization at discharge

Perioperative
Rate of device embolization
Lasso di tempo: At 30 days post-OP

Rate of device embolization at discharge at 30 days post-OP

At 30 days post-OP
Rate of device embolization
Lasso di tempo: At 3 months post-OP

Rate of device embolization at 3 months post-OP

At 3 months post-OP
Rate of death
Lasso di tempo: At 30 days

Rate of death at 30 days

At 30 days
Rate of death
Lasso di tempo: At 3 months post-OP

Rate of death at 3 months post-OP

At 3 months post-OP
Rate of death
Lasso di tempo: At 6 months post-OP

Rate of death at 6 months post-OP

At 6 months post-OP
Rate of death
Lasso di tempo: At 12 months post-OP

Rate of death at 12 months post-OP

At 12 months post-OP
Rate of device embolization
Lasso di tempo: At 6 months post-OP

Rate of device embolization at 6 months post-OP

At 6 months post-OP
Rate of device embolization
Lasso di tempo: At 12 months post-OP

Rate of device embolization at 12 months post-OP

At 12 months post-OP
Rate of major bleeding (BARC defined 3 to 5)
Lasso di tempo: Perioperative

Rate of major bleeding (BARC defined 3 to 5) at discharge

Perioperative
Rate of major bleeding (BARC defined 3 to 5)
Lasso di tempo: At 30 days post-OP

Rate of major bleeding (BARC defined 3 to 5) at 30 days post-OP

At 30 days post-OP
Rate of major bleeding (BARC defined 3 to 5)
Lasso di tempo: At 3 months post-OP

Rate of major bleeding (BARC defined 3 to 5) at 3 months post-OP

At 3 months post-OP
Rate of major bleeding (BARC defined 3 to 5)
Lasso di tempo: At 6 months post-OP

Rate of major bleeding (BARC defined 3 to 5) at 6 months post-OP

At 6 months post-OP
Rate of major bleeding (BARC defined 3 to 5)
Lasso di tempo: At 12 months post-OP

Rate of major bleeding (BARC defined 3 to 5) at 12 months post-OP

At 12 months post-OP
Closure success assessed by TEE or cardiac computed tomography
Lasso di tempo: At 30 days post-procedure

Closure success assessed by TEE or cardiac computed tomography at 30 days post-procedure

At 30 days post-procedure
Closure success assessed by TEE or cardiac computed tomography
Lasso di tempo: At 6 months post-procedure

Closure success assessed by TEE or cardiac computed tomography at 6 months post-procedure

At 6 months post-procedure
Closure success assessed by TEE or cardiac computed tomography
Lasso di tempo: At 12 months post-procedure

Closure success assessed by TEE or cardiac computed tomography at 12 months post-procedure

At 12 months post-procedure
Rate of minor bleeding (BARC type 2)
Lasso di tempo: At discharge, 30 days and 3, 6, 12 months post-procedure

Rate of minor bleeding (BARC type 2) at discharge

At discharge, 30 days and 3, 6, 12 months post-procedure
Rate of minor bleeding (BARC type 2)
Lasso di tempo: At 30 days post-procedure

Rate of minor bleeding (BARC type 2) at 30 days post-procedure

At 30 days post-procedure
Rate of minor bleeding (BARC type 2)
Lasso di tempo: At 3 months post-procedure

Rate of minor bleeding (BARC type 2) at 3 months post-procedure

At 3 months post-procedure
Rate of minor bleeding (BARC type 2)
Lasso di tempo: At 6 months post-procedure

Rate of minor bleeding (BARC type 2) at 6 months post-procedure

At 6 months post-procedure
Rate of minor bleeding (BARC type 2)
Lasso di tempo: At 12 months post-procedure

Rate of minor bleeding (BARC type 2) at 12 months post-procedure

At 12 months post-procedure
Rate of cardiovascular death
Lasso di tempo: Perioperative

Rate of cardiovascular death at discharge

Perioperative
Rate of cardiovascular death
Lasso di tempo: At 30 days post-procedure

Rate of cardiovascular death at 30 days post-procedure.

At 30 days post-procedure
Rate of cardiovascular death
Lasso di tempo: At 3 months post-procedure

Rate of cardiovascular death at 3 months post-procedure.

At 3 months post-procedure
Rate of cardiovascular death
Lasso di tempo: At 6 months post-procedure

Rate of cardiovascular death at 6 months post-procedure.

At 6 months post-procedure
Rate of cardiovascular death
Lasso di tempo: At 12 months post-procedure

Rate of cardiovascular death at 12 months post-procedure.

At 12 months post-procedure
Rate of ischemic stroke
Lasso di tempo: Perioperative

Rate of ischemic stroke at discharge

Perioperative
Rate of ischemic stroke
Lasso di tempo: At 30 days post-procedure

Rate of ischemic stroke at 30 days post-procedure

At 30 days post-procedure
Rate of ischemic stroke
Lasso di tempo: At 3 months post-procedure

Rate of ischemic stroke at 3 months post-procedure

At 3 months post-procedure
Rate of ischemic stroke
Lasso di tempo: At 6 months post-procedure

Rate of ischemic stroke at 6 months post-procedure

At 6 months post-procedure
Rate of ischemic stroke
Lasso di tempo: At 12 months post-procedure

Rate of ischemic stroke at 12 months post-procedure

At 12 months post-procedure
Rate of hemorrhagic stroke
Lasso di tempo: Perioperative

Rate of hemorrhagic stroke at discharge

Perioperative
Rate of hemorrhagic stroke
Lasso di tempo: At 30 days post-procedure

Rate of hemorrhagic stroke at 30 days post-procedure

At 30 days post-procedure
Rate of hemorrhagic stroke
Lasso di tempo: At 3 months post-procedure

Rate of hemorrhagic stroke at 3 months post-procedure

At 3 months post-procedure
Rate of hemorrhagic stroke
Lasso di tempo: At 6 months post-procedure

Rate of hemorrhagic stroke at 6 months post-procedure

At 6 months post-procedure
Rate of hemorrhagic stroke
Lasso di tempo: At 12 months post-procedure

Rate of hemorrhagic stroke at 12 months post-procedure

At 12 months post-procedure
Rate of systemic embolization
Lasso di tempo: Perioperative

Rate of systemic embolization at discharge

Perioperative
Rate of systemic embolization
Lasso di tempo: At 30 days post-procedure

Rate of systemic embolization at 30 days post-procedure

At 30 days post-procedure
Rate of systemic embolization
Lasso di tempo: At 3 months post-procedure

Rate of systemic embolization at 3 months post-procedure

At 3 months post-procedure
Rate of systemic embolization
Lasso di tempo: At 6 months post-procedure

Rate of systemic embolization at 6 months post-procedure

At 6 months post-procedure
Rate of systemic embolization
Lasso di tempo: At 12 months post-procedure

Rate of systemic embolization at 12 months post-procedure

At 12 months post-procedure
Procedural Technical success rate
Lasso di tempo: During procedure

Procedural Technical success rate, defined as successful delivery and release of study device with acceptable device position and stability, and closure success;

During procedure
Procedural success rate
Lasso di tempo: Peri-procedure

Procedural success rate, defined as technical success without major peri-procedural complications

Peri-procedure
Rate of Device-related thrombosis
Lasso di tempo: At 30 days post-procedure

Rate of Device-related thrombosis, defined as the detection of thrombus adherent to the left atrial side of the device by TEE or cardiac computed tomography at 30 days post-procedure

At 30 days post-procedure
Rate of Device-related thrombosis
Lasso di tempo: At 3 months post-procedure

Rate of Device-related thrombosis, defined as the detection of thrombus adherent to the left atrial side of the device by TEE or cardiac computed tomography at 3 months post-procedure

At 3 months post-procedure
Rate of Device-related thrombosis
Lasso di tempo: At 6 months post-procedure

Rate of Device-related thrombosis, defined as the detection of thrombus adherent to the left atrial side of the device by TEE or cardiac computed tomography at 6 months post-procedure

At 6 months post-procedure
Rate of Device-related thrombosis
Lasso di tempo: At 12 months post-procedure

Rate of Device-related thrombosis, defined as the detection of thrombus adherent to the left atrial side of the device by TEE or cardiac computed tomography at 12 months post-procedure

At 12 months post-procedure

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

5 marzo 2026

Completamento primario (Stimato)

1 novembre 2027

Completamento dello studio (Stimato)

1 maggio 2028

Date di iscrizione allo studio

Primo inviato

25 febbraio 2026

Primo inviato che soddisfa i criteri di controllo qualità

2 marzo 2026

Primo Inserito (Effettivo)

6 marzo 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

18 settembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

15 settembre 2026

Ultimo verificato

1 settembre 2026

Maggiori informazioni

Termini relativi a questo studio

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

NO

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi